Uterine sarcoma: Prognostic factors and treatment evaluation

Israel Medical Association Journal

Volumn 13, Issue 2, 2011, Pages 76-79

  Naaman, Yael ^a   Shveiky, David ^a   Ben Shachar, Inbar ^a   Shushan, Asher ^a   Mejia Gomez, Javier ^a   Benshushan, Abraham ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Overall survival; Prognostic factors; Treatment evaluation; Tumor characteristics; Uterine sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; ISRAEL; LEIOMYOSARCOMA; MEDICAL RECORD REVIEW; PROGNOSIS; RADIATION INJURY; RETROSPECTIVE STUDY; REVIEW; SALPINGOOOPHORECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA; UTERUS SARCOMA;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SARCOMA; UTERINE NEOPLASMS;

EID: 79952411345     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcoma: incidence and trends in management and survival. Gynecol Oncol 1997; 65: 158-63.
2. Pautier P, Genestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000; 88 (6): 1425-31.
3. Soumarová R, Horová H, Seneklová Z, et al. Treatment of uterine sarcoma. A survey of 49 patients. Arch Gynecol Obstet 2002; 266: 92-5.
4. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104: 179.
5. Ferrer F, Sabater S, Farrús B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the group oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999; 44: 47-52.
6. Coquard R, Romestaing P, Ardiet JM, Mornex F, Sentenac I, Géard JP. Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy [Abstract]. Bull Cancer 1997; 84 (6): 625-9.
7. Homesley HD, Filiaci V, Markman M, et al.; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol 2007; 25: 526-31.
8. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008; 199 (5): 536.e1-8.
9. Hardman MP, Roman JJ, Burnett AF, et al. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007; 110: 518-20.
10. Schwartz Z, Dgani R, Lancet M, Kessler I. Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 1985; 20 (3): 354-63.
11. Gottlieb S. Tamoxifen may increase risk for uterine sarcoma. BMJ 2002; 325: 7.
12. Lavie O, Barnett-Grinessy O, Narodz SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynaecol Cancer 2008; 18: 352-6.
13. Ben-Baruch G, Amir G, Menczer J, Bubis JH. Uterine sarcomas in Israeli patients: a clinicopathological study. Isr J Med Sci 1984; 20 (3): 211-15.
14. Steiner M, Lavie O, Leviov M, et al. Uterine sarcoma - accumulated 10 years experience [Abstract]. J Clin Oncol 2005; 16S: 5175.
15. Piura B, Rabinovich A, Yanai-Inbar I, Cohen Y, Glezerman M. Uterine sarcoma in the south of Israel: study of 36 cases. J Surg Oncol 1997; 64 (1): 55-62.
16. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116 (1): 131-9.